Article
Biochemistry & Molecular Biology
Shawn H. R. Lee, Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine R. R. Crews, Kathryn G. G. Roberts, Sima Jeha, Cheng Cheng, Seth E. E. Karol, Mary V. V. Relling, Gary L. L. Rosner, Hiroto Inaba, Charles G. G. Mullighan, Ching-Hon Pui, William E. E. Evans, Jun J. J. Yang
Summary: Contemporary chemotherapy for childhood acute lymphoblastic leukemia is personalized based on clinical features, leukemia genomics, and minimal residual disease. However, the pharmacological basis of these prognostic variables is unclear. A study analyzing samples from 805 children with newly diagnosed leukemia identified variations in drug response and determined that certain subtypes were more sensitive to specific agents. The findings suggest opportunities for individualizing therapy and exploring alternative strategies for childhood acute lymphoblastic leukemia.
Review
Oncology
Thai Hoa Tran, Stephen P. Hunger
Summary: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and has shown significant improvement in survival rates through risk-adapted chemotherapy, prevention measures, and molecular analysis. However, challenges remain for older patients and relapsed/refractory cases.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Genetics & Heredity
Samuel W. Brady, Kathryn G. Roberts, Zhaohui Gu, Lei Shi, Stanley Pounds, Deqing Pei, Cheng Cheng, Yunfeng Dai, Meenakshi Devidas, Chunxu Qu, Ashley N. Hill, Debbie Payne-Turner, Xiaotu Ma, Ilaria Iacobucci, Pradyuamna Baviskar, Lei Wei, Sasi Arunachalam, Kohei Hagiwara, Yanling Liu, Diane A. Flasch, Yu Liu, Matthew Parker, Xiaolong Chen, Abdelrahman H. Elsayed, Omkar Pathak, Yongjin Li, Yiping Fan, J. Robert Michael, Michael Rusch, Mark R. Wilkinson, Scott Foy, Dale J. Hedges, Scott Newman, Xin Zhou, Jian Wang, Colleen Reilly, Edgar Sioson, Stephen Rice, Victor Pastor Loyola, Gang Wu, Evadnie Rampersaud, Shalini C. Reshmi, Julie Gastier-Foster, Jaime M. Guidry Auvil, Patee Gesuwan, Malcolm A. Smith, Naomi Winick, Andrew J. Carroll, Nyla A. Heerema, Richard C. Harvey, Cheryl L. Willman, Eric Larsen, Elizabeth A. Raetz, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Patrick A. Zweidler-McKay, Karen R. Rabin, Leonard A. Mattano, Kelly W. Maloney, Stuart S. Winter, Michael J. Burke, Wanda Salzer, Kimberly P. Dunsmore, Anne L. Angiolillo, Kristine R. Crews, James R. Downing, Sima Jeha, Ching-Hon Pui, William E. Evans, Jun J. Yang, Mary Relling, Daniela S. Gerhard, Mignon L. Loh, Stephen P. Hunger, Jinghui Zhang, Charles G. Mullighan
Summary: A comprehensive analysis of genomic and transcriptomic data from 2,754 childhood acute lymphoblastic leukemias revealed 376 putative driver genes, as well as associations between disease subtypes and prognosis.
Article
Chemistry, Medicinal
Zulfan Zazuli, Lalu Muhammad Irham, Wirawan Adikusuma, Nur Melani Sari
Summary: This study utilizes high-throughput sequencing and genomic analysis to uncover the genetic heterogeneity of ALL and proposes potential drug development genes and drug repurposing candidates through genomic network analysis, providing guidance for the treatment of ALL.
Review
Biochemistry & Molecular Biology
Agnieszka Kaczmarska, Patrycja Sliwa, Joanna Zawitkowska, Monika Lejman
Summary: Pediatric acute lymphoblastic leukemia (ALL) with t(9;22)(q34;q11.2) is a rare malignancy in children, with approximately 3-5% of patients having the Philadelphia chromosome. Treatment outcomes have improved significantly in recent years, with tyrosine kinase inhibitor (TKI)-imatinib playing a key role in increasing overall survival for ALL Ph+ patients. Genetic analyses, particularly focusing on the IKZF1 gene, provide important prognostic information for pediatric ALL Ph+ cases, highlighting the need for targeted therapies and immunotherapy to enhance patient outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Zhenhua Li, Ti-Cheng Chang, Jacob J. Junco, Meenakshi Devidas, Yizhen Li, Wenjian Yang, Xin Huang, Dale J. Hedges, Zhongshan Cheng, Mary Shago, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Brent L. Wood, Michael J. Borowitz, Lauren Sanclemente, Elizabeth A. Raetz, Stephen P. Hunger, Eleanor Feingold, Tracie C. Rosser, Stephanie L. Sherman, Mignon L. Loh, Charles G. Mullighan, Jiyang Yu, Gang Wu, Philip J. Lupo, Karen R. Rabin, Jun J. Yang
Summary: This study investigates the genomics of Down syndrome-related acute lymphoblastic leukemia (DS-ALL) and identifies 15 molecular subtypes, as well as abnormal activation of key genes. It also reveals the common occurrence of somatic genomic abnormalities mediated by gene rearrangements in DS-ALL and the association between subtype heterogeneity and prognosis. These findings provide important insights into the biology of DS-ALL and offer opportunities for individualized treatment.
Article
Cell Biology
Yanxin Chen, Yongzhi Zheng, Yunda Hong, Jingjing Wen, Jiazheng Li, Yan Huang, Yi Chen, Xiaoyun Zheng, Ting Yang, Yangqi Xu, Jing Zheng, Jianda Hu
Summary: The prognosis of acute lymphoblastic leukemia in adults is inferior to that in children, and adults with ALL have a higher prevalence of genetic alterations. The number of gene mutations in adult ALL samples is higher than that in pediatric ALL samples and is correlated with age. Different driver genes are enriched in adult and pediatric ALL patients. Adult ALL patients have a higher incidence of relapse and poorer overall survival compared to pediatric ALL patients.
JOURNAL OF LEUKOCYTE BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Fabiana Cacace, Rossella Iula, Danilo De Novellis, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Rosanna Cuccurullo, William G. Wierda, Kris Michael Mahadeo, Giuseppe Menna, Francesco Paolo Tambaro
Summary: Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. Treatment includes chemotherapy and stem cell transplantation. Although prognosis has improved, it remains inferior to pediatric acute lymphoblastic leukemia.
Article
Biochemistry & Molecular Biology
Krzysztof Jedraszek, Marta Malczewska, Karolina Parysek-Wojcik, Monika Lejman
Summary: Despite advances in medicine, acute lymphoblastic leukemia (ALL) remains a challenge for pediatric clinicians due to treatment resistance and disease relapse. This article focuses on B-cell leukemia patients and examines prognostic factors, mechanisms of resistance to therapy, and the impact of genetic factors, including TCF3::HLF translocation. It also compares treatment protocols and explores the resistance of cancer cells to innovative therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Sarah Schober, Jennifer M. Rottenberger, Johannes Hilz, Evi Schmid, Martin Ebinger, Tobias Feuchtinger, Rupert Handgretinger, Peter Lang, Manon Queudeville
Summary: The immune environment plays a crucial role in various types of cancer. This study investigates the influence of Th1 cytokines on pediatric acute lymphoblastic leukemia (ALL). The findings suggest that TNF-alpha and IFN-gamma can induce apoptosis in ALL cells, though the reaction varies among different cells. The high expression of IFN-gamma receptor and subsequent activation of STAT1 are correlated with cell death.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Mateusz Gorecki, Ilona Koziol, Agnieszka Kopystecka, Julia Budzynska, Joanna Zawitkowska, Monika Lejman
Summary: The KMT2A gene is a common target for recurrent translocations in various types of leukemia, and its rearrangement has significant prognostic implications.
Review
Biochemistry & Molecular Biology
Anca Viorica Ivanov, Mirabela Smaranda Alecsa, Roxana Popescu, Magdalena Iuliana Starcea, Adriana Maria Mocanu, Cristina Rusu, Ingrith Crenguta Miron
Summary: In the past 40 years, the survival rate for pediatric cancer has greatly improved, reaching 75-80%. However, leukemia still remains a major cause of morbidity and mortality in specific patient populations. The future of leukemia treatment lies in molecular therapies, immune therapy, and cellular therapy. Recent advances in the field have led to the development of novel therapies for childhood leukemia, including targeted therapies and immunotherapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Genetics & Heredity
Olga Krali, Josefine Palle, Christofer L. Backlin, Jonas Abrahamsson, Ulrika Noren-Nystrom, Henrik Hasle, Kirsi Jahnukainen, Olafur Gisli Jonsson, Randi Hovland, Birgitte Lausen, Rolf Larsson, Lars Palmqvist, Anna Staffas, Bernward Zeller, Jessica Nordlund
Summary: This study explored the use of DNA methylation signatures to predict molecular subtypes and prognosis in pediatric acute myeloid leukemia (AML). Genome-wide DNA methylation analysis was conducted on diagnostic and relapse AML samples, leading to the development of DNA methylation-based classifiers with an overall test accuracy of 91%. Methylation signatures associated with specific cytogenetic subtypes were identified, highlighting the potential clinical value of DNA methylation analysis in AML.
Review
Medicine, General & Internal
Ilaria Iacobucci, Shunsuke Kimura, Charles G. Mullighan
Summary: Acute lymphoblastic leukemia (ALL) has achieved cure rates exceeding 90% in children, but remains a leading cause of cancer-related death in the young. Next generation sequencing has led to significant advances in understanding leukemogenesis and the development of novel therapeutic approaches, including mutation-specific and mutation-agnostic treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Jonathan D. Diedrich, Qian Dong, Daniel C. Ferguson, Brennan P. Bergeron, Robert J. Autry, Maoxiang Qian, Wenjian Yang, Colton Smith, James B. Papizan, Jon P. Connelly, Kohei Hagiwara, Kristine R. Crews, Shondra M. Pruett-Miller, Ching-Hon Pui, Jun J. Yang, Mary V. Relling, William E. Evans, Daniel Savic
Summary: The study reveals extensive chromatin reprogramming in ALL, with subtype-specific chromatin landscapes modulated by genetic variation. Differences in chromatin accessibility between ALL and normal B-cells suggest activation of repressed chromatin domains and disruption of normal B-cell development in ALL.
Article
Cardiac & Cardiovascular Systems
Louisa Gnatiuc, Roberto Tapia-Conyer, Rachel Wade, Raul Ramirez-Reyes, Diego Aguilar-Ramirez, William Herrington, Michael Hill, Sarah Lewington, Jason Torres, Eirini Trichia, Rory Collins, Richard Peto, Robert Clarke, Pablo Kuri-Morales, Jonathan R. Emberson, Jesus Alegre-Diaz
Summary: In this study of Mexican adults, abdominal adiposity (especially the waist-height ratio) was strongly and positively associated with vascular-metabolic mortality, while higher hip circumference was associated with lower vascular-metabolic mortality for a given amount of general and abdominal adiposity.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Letter
Oncology
Linea Natalie Toksvang, Kathrine Grell, Stine Nygaard Nielsen, Jacob Nersting, Daniel Murdy, Anthony V. Moorman, Ajay Vora, Kjeld Schmiegelow
Letter
Oncology
Mary M. Taj, Anthony V. Moorman, Lina Hamadeh, Arnaud Petit, Vahid Asnafi, Fanny Alby-Laurent, Ajay Vora, Marc R. Mansour, Rosemary Gale, Sylvie Chevret, John Moppett, Andre Baruchel, Elizabeth Macintyre
Article
Oncology
Linea N. Toksvang, Kathrine Grell, Jacob Nersting, Matilda Degn, Stine N. Nielsen, Jonas Abrahamsson, Bendik Lund, Jukka Kanerva, Olafur G. Jonsson, Kristi Lepik, Goda Vaitkeviciene, Laimonas Griskevicius, Petter Quist-Paulsen, Ajay Vora, Anthony Moorman, Daniel Murdy, Martin Zimmermann, Anja Moricke, Bruce Bostrom, Jaitri Joshi, Lisa L. Hjalgrim, Kim P. Dalhoff, Bodil Als-Nielsen, Kjeld Schmiegelow
Summary: The study found that in ALL patients, as the weighted mean DNA-TG increased, the risk of relapse decreased in MRD-positive patients, but not in MRD-negative patients. This indicates that DNA-TG may serve as a biomarker for maintenance therapy intensity.
Article
Hematology
Thomas Creasey, Emilio Barretta, Sarra L. Ryan, Ellie Butler, Amy A. Kirkwood, Daniel Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, Nick Morley, David Marks, Adele K. Fielding, Anthony Moorman
Summary: Despite being a childhood disease, acute lymphoblastic leukemia (ALL) also has a second peak in adults aged 60 years and over. However, existing treatment strategies have poor outcomes in this age group. Studies have shown that these older adults with ALL have common genetic abnormalities, indicating the need for novel therapeutic strategies to improve prognosis.
Article
Oncology
Richard Gallon, Rachel Phelps, Leigh Betts, Christine Hayes, Dino Masic, Julie A. E. Irving, Ciaron McAnulty, Vaskar Saha, Ajay Vora, Katharina Wimmer, Jayashree Motwani, Christine Macartney, John Burn, Michael S. Jackson, Anthony Moorman, Mauro Santibanez-Koref
LEUKEMIA & LYMPHOMA
(2023)
Meeting Abstract
Hematology
Hayden L. Bell, Mankaran Singh, Helen J. Blair, Olaf Heidenreich, Frederik W. van Delft, Anthony Moorman, John Lunec, Julie Irving
Meeting Abstract
Hematology
Angus Hodder, Avijeet K. Mishra, Katherine Clesham, Susan Baird, Kaljit Bhuller, Ismail Bisho, Denise Bonney, Anna Castleton, Michelle Cummins, Emmy Dickens, Lindsay George, Sara Ghorashian, Brenda Gibson, Chris Hasley, Nicholas Heaney, Rachael E. Hough, Danielle Ingham, Galina Jigoulina, Katherine Lindsay, Donna Lancaster, Majid Madni, Andrea Malone, Bethany Mitchell, Anthony Moorman, John Moppett, Vanessa McLelland, Jayashree Motwani, Emma Nicholson, Caroline Osborne, Katharine Patrick, Lamia Samrin, Sanjay Tewari, Indu Rakesh Thakur, Sujith Samarasinghe, Ajay Vora, David O'Connor
Meeting Abstract
Hematology
Daniel Leongamornlert, Jesus Gutierrez-Abril, SooWah Lee, Emilio Barretta, Thomas Creasey, Krisztina Zuborne Alapi, Max F. Levine, Juan E. Arango-Ossa, Juan S. Medina-Martinez, Amy A. Kirkwood, Laura Clifton-Hadley, Pip Patrick, David Jones, Adam P. Butler, Christine J. Harrison, Peter J. Campbell, Bela Patel Wrench, Anthony Moorman, Adele K. Fielding, Elli Papaemmanuil
Meeting Abstract
Hematology
Anna Ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony Moorman, Judith M. Boer, Frank N. van Leeuwen
Meeting Abstract
Hematology
David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy A. Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony Moorman, Ajay Vora, Marc R. Mansour
Meeting Abstract
Hematology
Angus Hodder, Avijeet K. Mishra, Susan Baird, Ismail Bisho, Denise Bonney, Katherine Clesham, Michelle Cummins, Emmy Dickens, Brenda Gibson, Lindsay George, Danielle Ingham, Galina Jigoulina, Donna Lancaster, Katherine Lindsay, Majid Madni, Andrea Malone, Bethany Mitchell, John Moppett, Jayashree Motwani, Anthony Moorman, Katharine Patrick, Lamia Samrin, Sanjay Tewari, Indu Rakesh Thakur, David O'Connor, Ajay Vora, Sujith Samarasinghe
Article
Hematology
Anna ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N. van Leeuwen
Summary: IKZF1 deletions have a significant negative impact on the survival of patients with ETV6::RUNX1 and high hyperdiploid ALL. The presence of IKZF1 deletions is associated with lower event-free survival rates, higher minimal residual disease values, and higher relapse rates in both ETV6::RUNX1 and high hyperdiploid ALL. Stratifying patients by minimal residual disease may not be sufficient for predicting outcomes in high hyperdiploid ALL, suggesting the need for additional risk stratification.
Article
Hematology
David Marks, Laura Clifton-Hadley, Mhairi Copland, Jiaull Hussain, Tobias F. Menne, Andrew McMillan, Anthony Moorman, Nicholas Morley, Dina Okasha, Bela Patel, Pip Patrick, Michael N. Potter, Clare J. Rowntree, Amy A. Kirkwood, Adele K. Fielding
Summary: This study evaluated the activity and safety of reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation (HSCT) in patients older than 40 years with acute lymphoblastic leukaemia. The results showed that this transplantation method provided good disease control with moderate graft-versus-host disease (GVHD) and achieved better-than-expected event-free survival and overall survival in this high-risk population.
LANCET HAEMATOLOGY
(2022)
Article
Hematology
David Marks, Amy A. Kirkwood, Clare J. Rowntree, Melanie Aguiar, Katharine E. Bailey, Brendan Beaton, Paul Cahalin, Anna Z. Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H. Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K. McMillan, Mary Frances McMullin, Tobias F. Menne, Rachel J. Mitchell, Anthony Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K. Fielding
Summary: The UKALL14 study aimed to determine the benefit of adding rituximab, an anti-CD20 monoclonal antibody, to the therapy of adults with acute lymphoblastic leukaemia. Results showed that adding rituximab did not significantly improve event-free survival for adults with de novo B-precursor acute lymphoblastic leukaemia.
LANCET HAEMATOLOGY
(2022)